New IVF Genetic Tests Promise Healthier Babies but Spark Ethical Debate

In a recent Vox podcast, journalist Kristen V. Brown explores the growing market for preimplantation genetic testing for polygenic risk (PGT-P), which allows IVF patients to assess embryos for complex conditions like heart disease, diabetes, and even non-medical traits such as height or eye colour. She notes that while the practice remains limited to a small number of families, more fertility doctors and companies are promoting it despite widespread disapproval from major medical societies.

Brown clarifies that embryo editing is currently illegal in the United States and most countries, though interest is rising for disease-prevention purposes. The discussion also references tech entrepreneur Brian Armstrong’s "Gattaca stack" concept, which envisions combining in-vitro gametogenesis, extensive embryo screening, and artificial wombs to produce idealized humans—a notion many compare to eugenics. Brown stresses the complexity of the genome and the impossibility of fully controlling a child’s traits, urging caution about the ethical implications of such technologies.